United Cannabis (CNABQ) 10-Q 16 Nov 17 2017 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Nov. 15, 2017
Document And Entity Information
Entity Registrant Name	United Cannabis Corp
Entity Central Index Key	1,436,161
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity's Reporting Status Current	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		60,210,502
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,017

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 647,697	$ 112,621
Account receivable, net	25,700	24,484
Due from related parties	37,283	26,775
Inventory	36,098
Total current assets	746,778	163,880
Outdoor cultivation facility and laboratory equipment, net of accumulated depreciation of $26,299 and $0.0 at September 30, 2017 and December 31, 2016, respectively	321,283
Patents, net	141,417
Intangible assets	73,043	32,273
Equity method investments		88,000
Goodwill	4,912,201
Total assets	6,194,722	284,153
Current liabilities:
Accounts payable	86,477	25,048
Accrued expenses	38,244	50,875
Current portion of deferred revenue	180,000	180,000
Advances from and accrued wages of officers and directors	587,943	175,592
Convertible notes payable		125,547
Total current liabilities	892,664	557,062
Scientific Research Grant	75,000
Deferred revenue, net of current portion	68,750	203,750
Total liabilities	1,036,414	760,812
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred stock, 10,000,000 shares authorized; 2,000 Series A shares and none outstanding at September 30, 2017 and December 31, 2016, respectively	2,200
Common stock, 100,000,000 shares authorized; 60,210,502 and 50,650,994 outstanding at September 30, 2017 and December 31, 2016, respectively	18,002,191	8,885,674
Accumulated deficit	(12,849,876)	(9,362,333)
Total equity (deficit) attributable to stockholders of the Company	5,154,515	(476,659)
Non-controlling interests (deficits) in less than fifty percent owned subsidiaries	3,793
Total stockholders' equity (deficit)	5,158,308	(476,659)
Total liabilities and stockholders' equity (deficit)	$ 6,194,722	$ 284,153

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Accumulated depreciation	$ 26,299	$ 0
Preferred stock, no par value
Preferred stock, shares authorized	10,000,000	10,000,000
Common stock, no par value
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares outstanding	60,210,502	50,650,994
Series A Preferred Stock [Member]
Preferred stock, shares issued	2,000	0
Preferred stock, shares outstanding	2,000	0

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenues
Revenues, non-affiliated	$ 57,627	$ 264,964	$ 277,685	$ 707,660
Revenues, affiliate	45,033		178,785
Total revenues	102,660	264,964	456,470	707,660
Cost of revenues	(26,226)	(68,813)	(238,227)	(252,550)
Gross Profit	76,434	196,151	218,243	455,110
Operating expenses
Marketing, advertising and new business development	39,728	7,516	132,493	56,208
Research and development	40,611	4,371	90,006	17,732
Legal, accounting, consulting and public reporting	181,052	111,847	637,252	246,584
General and administrative	461,990	(6,923)	2,644,041	225,748
Total operating expenses	723,381	116,811	3,503,792	546,272
Income (loss) from operations	(646,947)	79,340	(3,285,549)	(91,162)
Other income and costs and expenses
Gain (loss) on derivative liabilities		(331,618)		(332,456)
Loss on extinguishment of debt			(267,567)	(130,423)
Interest expense	(6,759)	(40,044)	(54,432)	(153,438)
Amortization of debt discount				(266,711)
Gain on conversion of a portion of convertible notes		(4,253)		11,237
Loss on settlement of dispute			(122,139)
Loss before provision for taxes on income	(653,706)	(296,575)	(3,729,687)	(962,953)
Provision for taxes on income
Net Income (Loss)	(653,706)	(296,575)	(3,729,687)	(962,953)
Loss attributable to non-controlling interests	80,914		242,146
Net (Loss) attributable to common shareholders	$ (572,792)	$ (296,575)	$ (3,487,541)	$ (962,953)
Basic loss per common share	$ (0.01)	$ (0.01)	$ (0.07)	$ (0.02)
Basic and fully diluted weighted average number of shares outstanding	56,503,689	44,925,837	54,170,003	45,519,746

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash flows from operating activities:
Net loss	$ (3,729,687)	$ (962,953)
Increase in collection reserve		25,660
Amortization of debt discount to interest expense	34,453	266,711
Decrease in deferred financing costs		32,400
Depreciation and amortization	26,299
Share-based compensation	2,117,302	118,160
Loss on revaluation of derivative liability		365,576
Loss on extinguishment of debt	248,892
Loss on settlement of dispute	122,139
Loss on warrants to cure debt default		92,004
Loss on modification of note payable		133,077
Gain on payoff of convertible notes		(156,531)
Gain on conversion of convertible note		(11,237)
Discount on and fees on convertible note payable		15,500
Changes in operating assets and liabilities
Accounts receivable	(1,216)	(279)
Amounts due from related parties	(10,508)
Inventory	(36,098)
Prepaid expenses		56,341
Accounts payable and accrued expenses	23,271	72,634
Deferred revenue	(135,000)	(335,000)
Accrued wages payable to officers and directors	302,889	29,330
Net cash used in operating activities	(1,037,264)	(258,607)
Investing activities:
Cash acquired upon acquisition of subsidiary	347,307
Improvements to cultivation facility and purchase of equipment	(261,560)
Purchase of intangible assets	(125,858)
Return of deposit	(32,500)
Cash portion of settlement of dispute	(20,000)
Net cash used in investing activities	(92,611)
Cash flow from financing activities:
Proceeds from issuance of common stock - equity financing line	1,380,204
Proceeds from convertible notes		316,478
Advances from officers and directors	254,943	52,500
Repayment of convertible debt and notes payable	(35,000)	(213,978)
Proceeds from sale of common stock and exercise of warrants	64,804
Net cash provided by financing activities	1,664,951	155,000
Net increase (decrease) in cash	535,076	(103,607)
Cash and equivalents, beginning of period	112,621	118,420
Cash and equivalents, end of period	647,697	14,813
Supplemental cash flow disclosures
Cash paid for interest
Cash paid for income taxes
Supplemental disclosure of non-cash investing and financing activities
Issuance of stock options in exchange for accrued wages payable to officers and directors		612,512
Issuance of common stock upon conversion of convertible note payable to Tangiers Investment Group		473,965
Reduction of convertible notes payable due to the conversion by Tangiers Investment Group		220,000
Common shares issued in the acquisition of Prana Therapeutics, Inc.	4,870,500
Exercise of stock option for 1,000,000 of common stock in exchange for notes payable to an officer and director	200,000
Decrease in non-marketable securities due to the exchange of 1,100,000 shares of common stock of WeedMD		(190,150)
Reduction of notes payable due to assumption of note payable to WeedMD by unrelated third party in exchange for the exchange of 1,100,000 shares of common stock of WeedMD		175,000
Acquisition from and leaseback to of equipment to related party	99,200
Accounts payable exchanged for note payable to third party		$ 30,000

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (Parenthetical)	9 Months Ended
	Sep. 30, 2017shares
Officer and Director [Member]
Notes payable in exchange for shares of common stock	1,000,000
WeedMD RX Inc. (''WMD'') [Member]
Notes payable in exchange for shares of common stock	1,100,000

BUSINESS ORGANIZATION AND NATUR

BUSINESS ORGANIZATION AND NATURE OF OPERATIONS	9 Months Ended
	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BUSINESS ORGANIZATION AND NATURE OF OPERATIONS	NOTE 1 –BUSINESS ORGANIZATION AND NATURE OF OPERATIONS Background and Current Operations United Cannabis Corporation ("we", "our", "us", "UCANN", or “the Company”) a Colorado corporation, was originally formed as a California corporation under the name MySkin, Inc. on November 15, 2007. MySkin was engaged in the business of providing management services to a medical spa in Los Angeles, California which provided various advanced skin care services until March 31, 2014, when this business was sold to the prior President of the Company. In early 2014 we decided to exit the medical spa management business and change our focus to providing products, services and intellectual property to the cannabis industry. On March 26, 2014, we entered into a License Agreement with Earnest Blackmon, Tony Verzura and Chad Ruby pursuant to which Messrs. Blackmon, Verzura and Ruby licensed certain intellectual property to us in exchange for a total of 38,690,000 shares of our common stock. In connection with this transaction: · Messrs. Blackmon, Verzura and Ruby licensed to us all of their knowledge and know-how relating to the design and buildout of cultivation facilities, growing/cultivation systems, seed-to-sale protocols and procedures, products, a genetic catalogue including over 150 different strains, an advanced (non-psychoactive) cannabinoid therapy program called "A.C.T. Now", security, regulatory compliance, and other methods and processes which relate to the cannabis industry. · The territory for this license is the entire world and the license runs in perpetuity. There are no royalty payments under the License Agreement. · Messrs. Blackmon, Verzura and Ruby were appointed to our board of directors effective April 7, 2014. · Mr. Blackmon was elected as our President, Mr. Ruby was elected as Chief Operating Officer and Mr. Verzura was elected as Vice President. · A total of 41,690,000 previously outstanding shares of common stock were cancelled resulting in a total of 43,620,000 shares of common stock outstanding on March 26, 2014. UCANN was formed as a Colorado corporation on March 25, 2014, and on May 2, 2014, MySkin, Inc. merged into UCANN, a wholly-owned subsidiary of MySkin, Inc., for the purpose of changing domicile from California to Colorado and changing the corporation's name to United Cannabis Corporation. On March 31, 2014, we sold all right, title and interest in the tangible and intangible assets, trademarks, customer lists, intellectual property and rights, which we owned and were related to our advanced skin care business since we entered into a new business and no longer had any use for these assets. The assets were sold to MySkin Services, Inc. (“MTA”), a business partly owned by Marichelle Stoppenhagen, our former officer and director, in exchange for the $15,000 payable which we owed to Ms. Stoppenhagen and/or MTA. In addition, MTA assumed all costs associated with these assets starting on March 31, 2014. On July 14, 2017, we completed the acquisition of Prana Therapeutics, Inc. (“Prana”) in a one-for-one exchange of 5,730,000 shares of common stock of the Company for 5,730,000 of common stock of Prana. The purchase price had a fair market value of $5,070,500, based upon the closing price of $0.85 per share on the OTC QB exchange on July 14, 2017, including the cost to purchase 400,000 shares of Prana common stock for $200,000. Prana is a polymolecular botanical drug development company focused on developing targeted therapeutics for prevention of the negative side effects of chemotherapy, management of rheumatoid arthritis and treatment of brain cancer. Management elected to purchase Prana, because of the successful indication of the effectiveness of their Epidiferphane™ chemical formulation in the treatment of (i) the negative side effects of chemotherapy, (ii) inflammation and pain associated with arthritis and back-centric pain, (iii) sleep disorder, and (iv) the potential shrinkage of brain tumors. Government Regulation As of September 30, 2017, 28 states and the District of Columbia allow their citizens to use medical marijuana, and voters in the states of California, Colorado, Washington, Nevada, Oregon, Alaska and the District of Columbia approved ballot measures to legalize cannabis for adult recreational use. The state laws are in conflict with the federal Controlled Substances Act, which makes marijuana use and possession illegal on a national level. The former Obama administration has effectively stated that it is not an efficient use of resources to direct federal law enforcement agencies to prosecute those lawfully abiding by state-designated laws allowing the use and distribution of medical and recreational marijuana. However, there is no guarantee that the current administration will not change its stated policy regarding the low-priority enforcement of federal laws, or that any future administration would not change this policy and decide to enforce the federal laws vigorously. Any such change in the federal government’s enforcement of current federal laws could cause significant financial damage to us.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation Principles of Consolidation Use of Estimates We make our estimates of the ultimate outcome for these items based on historical trends and other information available when our condensed consolidated financial statements are prepared. We recognize changes in estimates in accordance with the accounting rules for the estimates, which are typically in the period when new information becomes available. We believe that our significant estimates, assumptions and judgments are reasonable, based upon information available at the time they were made. Our actual results could differ from these estimates, making it possible that a change in these estimates could occur in the near term. Fair Value of Financial Instruments Level 1 Level 2 Level 3 The carrying amount of our cash and cash equivalents, accounts receivable, accounts payable, and other current assets and liabilities in our consolidated financial statements approximates fair value because of the short-term nature of the instruments. Investments in non-marketable equity securities are carried at cost less other-than-temporary impairments. The carrying amount of our notes payable and convertible debt at September 30, 2017, approximates their fair values based on our incremental borrowing rates. There have been no changes in Level 1, Level 2, and Level 3 categorizations and no changes in valuation techniques for these assets or liabilities for the nine months ended September 30, 2017 and the year ended December 31, 2016. Cash and Cash Equivalents Accounts Receivable Prepaid Expenses Property and Equipment Patents – Intangible Assets – Long-Lived Assets Impairment Assessment FASB Accounting Standards Codification Equity Method Investments Goodwill Purchase Price Allocation Business Combinations Fair Value Measurements and Disclosures Deferred Revenue Revenue Recognition Revenue Recognition Revenue for services with a payment in the form of stock, warrants or other financial assets is recognized when the services are performed. The value of revenue paid with warrants is measured using the Black-Scholes-Merton pricing model. Revenue from product sales, including delivery fees, is recognized when an order has been obtained, the price is fixed and determinable, the product is shipped, title has transferred, and collectability is reasonably assured. Revenue Recognition – Affiliate Prana Prana Prana Prana Prana Prana Revenue Recognition. Cost of Revenues Research and Development Expenses General and Administrative Expenses Stock-Based Compensation Equity We account for stock option grants issued and vesting to employees based on ASC 718, Compensation – Stock Compensation Income Taxes We follow the provisions of ASC 740, Income Taxes When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken, or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in our consolidated financial statements in the period during which, based on all available evidence, we believe it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured, as described above, is reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets, along with any associated interest and penalties that would be payable to the taxing authorities upon examination. Interest and penalties associated with unrecognized tax benefits, if any, are classified as interest expense and penalties and are included in selling, general and administrative expenses in our consolidated statements of operations. Commitments and Contingencies If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in our condensed consolidated financial statements. If the assessment indicates that a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the nature of the guarantee would be disclosed. Net Loss Per Share Earnings per Share Potentially dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share, because the effect of their inclusion would have been anti-dilutive: Nine Months Ended Three Months Ended 2017 2016 2017 2016 Warrants to purchase common stock 641,000 666,667 641,000 666,667 Cashless warrants not converted to common stock 783,112 1,228,455 783,112 1,228,455 Stock options 6,580,000 3,680,000 6,580,000 3,680,000 8,004,112 5,575,122 8,004,112 5,575,122 Other Comprehensive Income (Loss) Segment Reporting – Concentration of Credit Risk The following tables show significant concentrations in our revenues and accounts receivable for the periods indicated: Percentage of Revenue: Nine Months Ended Three Months Ended September 30, September 30, 2017 2016 2017 2016 Customer A 82 % 88 % 98 % 80 % Customer B 17 % 12 % 2 % 20 % Customer C 1 % 0 % 0 % 0 % Percentage of Accounts Receivable: Nine Months Ended 2017 2016 Customer A 0 % 68 % Customer B 0 % 30 % Customer C 0 % 21 % Recently Issued Accounting Pronouncements In May 2014 the FASB issued guidance on revenue from contracts with customers, which implements a five-step process of how an entity should recognize revenue in order to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This guidance will be effective at the beginning of fiscal year 2018, and early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. We are currently evaluating the impact that the adoption will have on our condensed consolidated financial statements and related disclosures. We have not yet selected a transition method nor have we determined the effect of the standard on our ongoing reporting. In February 2016, the FASB issued guidance on leases which requires entities to recognize right-of-use assets and lease liabilities on the balance sheet for the rights and obligations created by all leases, including operating leases, with terms of more than 12 months. The new guidance also requires additional disclosures on the amount, timing, and uncertainty of cash flows arising from leases. These disclosures include qualitative and quantitative information. The new guidance will be effective for us at the beginning of fiscal year 2019. Early adoption is permitted. We are in the process of evaluating the impact the adoption of this guidance will have on our consolidated financial statements and related disclosures.

GOING CONCERN

GOING CONCERN	9 Months Ended
	Sep. 30, 2017
GOING CONCERN [Abstract]
GOING CONCERN	NOTE 3 – GOING CONCERN Our condensed consolidated financial statements have been prepared on a going concern basis which assumes we will be able to realize our assets and discharge our liabilities in the normal course of business for the foreseeable future. During the nine months ended September 30, 2017, we incurred losses of $3,729,687 and used cash of $1,037,264 in our operating activities. At September 30, 2017, we had a working capital deficit of $145,886 and an accumulated deficit of $12,849,876. We have an equity line of credit funding agreement for providing equity capital for up to $10,000,000 of funding through the purchase of shares of our common stock. During the term of the agreement, the Company may deliver a put notice to the financier, which will specify the number of shares which we will sell to the financier. As of September 30, 2017, we have received $1,380,204, under the terms of the equity line of credit agreement. However, our ability to continue as a going concern is dependent upon our ability to generate profitable operations in the future and, or, to able to draw funds from our equity line of credit agreement. There is no assurance that these events will be satisfactorily completed.

RECEIVABLE FROM AND EQUIPMENT N

RECEIVABLE FROM AND EQUIPMENT NOTE PAYABLE TO RELATED PARTY	9 Months Ended
	Sep. 30, 2017
Related Party Transactions [Abstract]
RECEIVABLE FROM AND EQUIPMENT NOTE PAYABLE TO RELATED PARTY	NOTE 4 – RECEIVABLE FROM AND EQUIPMENT NOTE PAYABLE TO RELATED PARTY On April 20, 2015, we advanced Cannabinoid Research & Development, Limited (“CRD”) $5,000 and included this amount in due from related parties. At March 31, 2017, we concluded that we had established a variable interest entity relationship with CRD, because we are the primary beneficiary, in accordance with GAAP. As a result, we elected to consolidate the assets and liabilities of CRD in our consolidated balance sheet at March 31, 2017. Thus, at September 30, 2017, the $5,000 advance to CRD is eliminated upon the consolidation of the assets and liabilities of CRD for financial statement reporting purposes. In the normal course of business, we make non-interest bearing advances to Advesa, Inc. (“Advesa’), which is 100% owned by one of our officers and directors. Such advances are used by Advesa to purchase equipment and to cover the cost of their operations. Amounts due from related parties consist of: September 30, December 31, 2017 2016 Advesa, Inc. $ 35,083 $ 21,775 Employees 2,200 — Cannabinoid Research & Development, Limited — 5,000 $ 37,283 $ 26,775 We purchased certain laboratory equipment from Advesa at an amount equal to their cost of the equipment, and subsequently leased the laboratory equipment back to Advesa for a 36 month period. The equipment note is payable over 36 months at an interest rate of $7.5%. The equipment note was paid in full on August 1, 2017.

PURCHASE OF PRANA THERAPUETICS,

PURCHASE OF PRANA THERAPUETICS, INC.	9 Months Ended
	Sep. 30, 2017
Business Combinations [Abstract]
PUCHASE OF PRANA THERAPUETICS, INC.	NOTE 5 – PURCHASE OF PRANA THERAPUETICS, INC. On June 8, 2017, we entered into an agreement to purchase 400,000 shares of Prana Therapeutics, Inc. (“Prana”), in a private offering of their common shares, for a total consideration of $200,000 (“Subscription Agreement’). In accordance with the terms of the Subscription Agreement, we paid Prana $50,000, upon execution of the Subscription Agreement, and committed to remit $50,000 to Prana on September 30, 2017, December 31, 2017 and March 31, 2018, respectively. Subsequently, on July 14, 2017, we completed the acquisition of Prana in a one-for-one exchange of 5,730,000 shares of our common stock for 5,730,000 shares of common stock of Prana. The purchase price had a fair market value of $5,070,500, based upon the closing price of $0.85 per share of our common stock on the OTC QB exchange on July 14, 2017, including the cost to purchase 400,000 shares of Prana for $200,000. The purchase price for Prana was allocated to the net tangible and intangible assets based upon their fair values as of the acquisition date. The excess of the purchase price over the fair values of the net tangible assets and intangible assets was recorded as goodwill and is generally driven by management’s expectations and ability to realize synergies and achieve strategic growth. As of July 14, 2017, the allocation of the purchase price for the 95% fair value of Prana was comprised of: Patents $ 52,596 Net assets 450,888 Goodwill 4,567,016 Total $ 5,070,500

PATENTS

PATENTS	9 Months Ended
	Sep. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
PATENTS	NOTE 6 -PATENTS On August 15, 2017, the United States Patent and Trademark Office issued to the Company US Patent #9730911 (the “Patent”) granting exclusive rights to its proprietary formulations based on compounds extracted from cannabis plant materials; more specifically the composition of matter pertaining to the use of phytocannabinoids, cannabinoids, and specific terpene profiles in liquid form. This composition of matter Patent provides protection for our proprietary formulations. The Patent protects the use of suspending both phytocannabinoids and cannabinoids with specific combinations of cannabis derived terpenes in liquid forms with an array of delivery methods including capsule, sublingual, topical, oral, suppository, and vaporization. Cannabinoids referenced in the application include ratios of tetrahydrocannabinolic acid (THCa), cannabidiolic acid (CBDa), tetrahydrocannabinol (THC), cannabinol (CBN), cannabidiol (CBD), cannabichromenic acid (CBCa), and cannabichromene (CBC). At August 15, 2017, we classified the costs associated with research, legal fees, application costs incurred in the process of being granted the Patent on our consolidated balance sheet in the amount of $142,317, and we began amortizing such cost of the Patent on a straight-line basis over a 15 year period. Amortization expense of the Patent is $900 and $0.00 for the nine months ended September 30, 2017 and 2016, respective, and accumulated amortization is $900 and $0.00 at September 30, 2017 and 2016, respectively.

INTANGIBLES

INTANGIBLES	9 Months Ended
	Sep. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLES	NOTE 7 – INTANGIBLES Our intangible assets are comprised of the costs incurred in pursuing provisional patent applications and applications for design mark and trademarks, which have presently not been approved or issued. The costs associated with our intangible assets are amortized on a straight-line basis over estimated useful lives of 15 years for patents and 10 years for design marks and trademarks, once the applications are approved. Costs associated with applications that are not approved will be expensed in the period that the application is rejected or abandoned.

EQUITY METHOD INVESTMENTS

EQUITY METHOD INVESTMENTS	9 Months Ended
	Sep. 30, 2017
Equity Method Investments and Joint Ventures [Abstract]
EQUITY METHOD INVESTMENTS	NOTE 8 – EQUITY METHOD INVESTMENTS On August 15, 2014, we acquired a 50% interest in Cannabinoid Research & Development Company Limited (“CRD”), a Jamaican company, in exchange 40,000 shares of our common stock valued at $88,000 based on the previous day’s closing price of our stock. We also committed to provide expertise on design-build, genetics, cultivation, production, processing, productizing, labeling, packaging, marketing, branding and distribution of products, as well as use of our intellectual property in the operations of CRD. We accounted for this $88,000 as an equity method investment on our condensed consolidated balance sheets at December 31, 2016. At March 31, 2017, it was concluded that we had established a variable interest entity relationship with CRD, because we are the primary beneficiary, in accordance with GAAP. As a result, we elected to consolidate the assets and liabilities of CRD in our consolidated balance sheet at March 31, 2017.

ACCRUED EXPENSES

ACCRUED EXPENSES	9 Months Ended
	Sep. 30, 2017
Accrued Liabilities, Current [Abstract]
ACCRUED EXPENSES	NOTE 9 – ACCRUED EXPENSES Our accrued expenses consist of: September 30, 2017 December 31, 2016 Accrued consulting fees $ — $ 45,000 Accrued interest expense — 5,875 Accrued payroll taxes 38,244 — $ 38,244 $ 50,875 On May 6, 2014, we entered into a consultancy agreement with two third party consultants that had a nine month term, which could be renewed and/or extended by mutual agreement. The agreement provided for a $50,000 payment at signing, which has been paid, and for three more $50,000 payments (a total of $200,000) and the issuance of 100,000 shares of our common stock upon the achievement of certain goals, as set forth in appendix II of the agreement. During the year ended December 31, 2014 we recognized $160,000 of expense applicable to this agreement. At December 31, 2015, the project was approximately 80% complete and $110,000 was included in accrued expenses on our consolidated balance sheet at that date. On December 7, 2016, upon mutual agreement, the consultancy agreement was deemed to be abandoned, because the project was not completed. In turn, one of the consultants, Dr. Brent Reynolds, has been performing other services for us during the year ended December 31, 2016, and has agreed to join our Board of Advisors. Dr Reynolds is currently a professor in the Department of Neurosurgery at the University of Florida, College of Medicine, where his lab focuses on the application of natural products for treating diseases and dysfunction of the nervous system. In recognition of his services to us during the year ended December 31, 2016, and as an inducement to join our Board of Advisors, he was issued 100,000 shares of our common stock for such services, and the fair market value of these shares in the amount of $163,783 was credited to stockholders’ equity (deficit) on the consolidated balance sheet at December 31, 2016, and the residual amount of $53,783 was recognized as a loss on the extinguishment of a debt in our consolidated statement of operations.

FAIR VALUE MEASUREMENTS AND DER

FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITIES	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITIES	NOTE 10 – FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITIES We did not have any liabilities carried at fair value measured on a recurring basis as of September 30, 2017 or at December 31, 2016.

RESEARCH GRANT PAYABLE

RESEARCH GRANT PAYABLE	9 Months Ended
	Sep. 30, 2017
Other Liabilities Disclosure [Abstract]
RESEARCH GRANT PAYABLE	NOTE 11 – RESEARCH GRANT PAYABLE In August of 2013, we were received a grant from Accelerate Brain Cancer Cure, Inc. (“ABC”) in the amount of $75,000 to be used by us for the development and testing of brain cancer therapies (the “Grant”). Under the terms of the Grant, within 15 years after the effective date of the Grant, if one or more products resulting from the Grant is brought to market, then the Company will owe ABC the repayment of the Grant in the following amounts, based upon the following cumulative net profit benchmarks: Net Profit Grant $ 5,000,000 $ 75,000 15,000,000 75,000 30,000,000 75,000 50,000,000 75,000 $ 300,000

DEFERRED REVENUE

DEFERRED REVENUE	9 Months Ended
	Sep. 30, 2017
Deferred Revenue Disclosure [Abstract]
DEFERRED REVENUE	NOTE 12 – DEFERRED REVENUE Our deferred revenue consists of: September 30, December 31, Deferred revenue - WeedMD $ 248,750 $ 383,750 Less - current portion (180,000 ) (180,000 ) Deferred revenue, net of current portion $ 68,750 $ 203,750 As described in Note 4 above, on June 9, 2014, we received 1,187,500 common shares and 3,000,000 warrants to purchase common shares of WMD in exchange for future consulting services and use of our intellectual property. We recorded the $893,750 fair value of these securities as deferred revenue, and we recognized $150,000 of this amount as revenue during the period July 1, 2014 through December 31, 2014, based upon our initial three year estimate of the service period involved. Based on consultations with WMD, we expect to deliver the remaining consulting services and use of our intellectual property to WMD on a relatively consistent monthly basis during the four year period January 1, 2016 through December 31, 2018. Accordingly, we are now recognizing $15,000 of deferred revenue per month, and thus, during the three and nine month periods ending September 30, 2017 and 2016, we recognized a total of $45,000 and $90,000, respectively, of revenue applicable to this arrangement. At September 30, 2017, we expect to recognize $180,000 of the remaining $248,750 WMD deferred revenue during the next twelve months and accordingly, we have classified the $180,000 as a current liability on our condensed consolidated balance sheets. On December 28, 2014, we entered into a royalty and consulting services agreement with FoxBarry Farms, LLC (“FoxBarry”) whereby we received a $200,000 prepaid royalty payment from FoxBarry. At the time, we planned to recognize deferred royalty revenue based on actual applicable sales as defined in the agreement. During the years ended December 31, 2015 and 2014, we did not recognize any deferred revenue related to this agreement. In August 2015, we discontinued providing consulting services to FoxBarry, as our initial project with FoxBarry was abandoned due to operational issues. However, FoxBarry appears to no longer be in existence, and since all of our conditions pursuant to the agreement have been satisfied, we elected to recognize the $200,000 of deferred income during the year ended December 31, 2016, as other income .

NOTES PAYABLE

NOTES PAYABLE	9 Months Ended
	Sep. 30, 2017
Notes Payable [Abstract]
NOTES PAYABLE	NOTE 13 – NOTES PAYABLE We do not owe any notes payable at September 30, 2017 or December 31, 2016.

STOCKHOLDERS' EQUITY (DEFICIT)

STOCKHOLDERS' EQUITY (DEFICIT)	9 Months Ended
	Sep. 30, 2017
Stockholders' Equity Note [Abstract]
STOCKHOLDERS' EQUITY (DEFICIT)	NOTE 14 – STOCKHOLDERS’ EQUITY (DEFICIT) Stock Options On January 9, 2016, we awarded 200,000 stock options to each of Messrs. Blackmon, Verzura and Ruby under our 2014 Stock Incentive Plan. The options were fully vested at the time of grant and give the option holder the right to purchase shares of our common stock at $0.70 per share during the ten year term of the option. We calculated the fair value of each option to be approximately $0.70 per option utilizing the Black Scholes option pricing model and the following assumptions on the date of valuation: Stock price $ 0.70 Exercise price $ 0.70 Risk free interest rate 1.98 % Expected term (years) 10.0 Expected volatility 173 % Expected dividends 0 % At December 31, 2016, the fair value of these 600,000 options totaling $417,664 was included in accrued expenses on our condensed consolidated balance sheets and on January 9, 2016, the option grant date, we increased common stock and decreased accrued expenses by this amount to account for the issuance of these options on that date. On January 12, 2016, we awarded 1,050,000 stock options to each of Messrs. Blackmon, Verzura and 980,000 stock potions to Mr. Ruby under our 2014 Stock Incentive Plan. The options were fully vested at the time of grant and give the option holder the right to purchase shares of our common stock at $0.20 per share during the ten year term of the option. We calculated the fair value of each option to be approximately $0.20 per option utilizing the Black Scholes option pricing model and the following assumptions on the date of valuation: Stock price $ 0.20 Exercise price $ .20 Risk free interest rate 1.98 % Expected term (years) 10.0 Expected volatility 173 % Expected dividends 0 % On May 31, 2017, we awarded 100,000 stock options to each of Messrs. Blackmon, Verzura, 100,000 stock options to a non-officer consultant, and 2,600,000 stock options to Mr. Ruby under our 2017 Stock Incentive Plan. The options were fully vested at the time of grant, and give the option holder the right to purchase shares of our common stock at $0.56 per share during the ten year term of the option. We calculated the fair value of each option to be approximately $0.56 per option, based upon the day’s closing price of our common stock on the date of grant. At December 31, 2016, the fair value of 3,080,000 options totaling $612,512, was included in accrued expenses on our condensed consolidated balance sheets, and on January 15, 2017, the option grant date, we increased common stock and decreased accrued expenses by this amount to account for the issuance of these options on that date. The following table summarizes our stock options outstanding, as of September 30, 2017: Nine Months Ended September 30, 2017 Number of Shares Weighted Average Remaining Life (years) Weighted Average Exercise Price Stock options outstanding, beginning of period 3,680,000 8.9 $ $0.28 Issued 2,900,000 9.6 $0.56 Exercised — Expired — Stock options outstanding, end of period 6,580,000 8.8 $ $0.40 Stock options exercisable, September 30, 2017 6,580,000 8.8 $ $0.40 We issued to certain of our employees 57,500 stock options, at an option price of $0.92 per share that will become vested and exercisable on July 26, 2018. Common Stock Issued In Exchange For Warrant Outstanding On February 10, 2016, we issued 621,000 shares of our common stock valued at $987,390 based on the previous day’s closing price, to Typenex Co-Investment, LLC ("Typenex") in exchange for the return of Warrant #1 to Purchase Shares of Common Stock (the “Warrant”) that we issued to Typenex on August 13, 2014, as part of a financing arrangement. We calculated the fair value of the Warrant to be $218,788, or approximately $1.29 per underlying share, utilizing the Black Scholes option pricing model and the following assumptions on the date of valuation: Stock price $ 1.59 Exercise price $ 3.00 Risk free interest rate 1.05 % Expected term (years) 2.6 Expected volatility 183 % Expected dividends 0 % The Warrant gave Typenex the right to purchase 170,044 shares of our common stock on the issuance date and provided for adjustments to the number of shares underlying the Warrant upon occurrence of certain events including subsequent sales of our common stock. Our repurchase of the Warrant resulted in Typenex forgoing its potential right to receive shares in excess of the original 170,044 shares underlying the Warrant on the original issuance date. On February 10, 2016, we recorded the $768,602 fair value of the common shares issued in excess of the $218,788 fair value of the Warrant reacquired as a loss on settlement of disputed terms of warrant in our condensed consolidated statements of operations and as an increase in common stock on our condensed consolidated balance sheets. On February 10, 2016, we cancelled the Warrant and recorded the $218,788 fair value as an increase to common stock. Warrants: The following table summarizes our share warrants outstanding as of September 30, 2017 and December 31, 2016: September 30, 2017 December 31, 2016 Number Weighted Number Weighted Warrants outstanding, beginning of period 1,449,779 $ 0.18 3,000,000 $ 12.00 Warrants issued to consultant 83,333 0.18 666,667 0.18 Warrants issued to consultant 16,000 1.25 — — Cashless issued upon conversion of Slainte note — 1,746,674 — Warrants exercised (125,000 ) 0.18 (963,562 ) — Expired — — (3,000,000 ) — Warrants outstanding, end of period 1,424,112 $ 0.19 1,449,779 $ 0.18 Warrants exercisable, end of period 1,424,112 $ 0.19 1,449,779 $ 0.18 Preferred Stock On July 18, 2017, the Board of Directors adopted a resolution creating a series of Preferred Shares, no par value per share, designated as the Series A Preferred Shares. We subsequently issued 2,000 shares of our Series A preferred stock for $2,200 to of our officers and directors.

SHARE-BASED COMPENSATION

SHARE-BASED COMPENSATION	9 Months Ended
	Sep. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
SHARE-BASED COMPENSATION	NOTE 15 – SHARE-BASED COMPENSATION Share-based Compensation We recognize share-based compensation expense in cost of revenues and general and administrative expense based on the fair value of common shares issued for services. Share-based compensation expense for the three and nine months ended September 30, 2017 and 2016 is, as follows: Three Months Ended Nine Months Ended 2017 2016 2017 2016 Options granted to officers and directors for compensation $ — $ 33,780 $ 1,812,456 $ 118,160 Warrants and options issued for consulting services — — 16,379 — Common stock issued for services 68,984 — 170,958 — Common stock accrued as payment for services, shares not yet issued 22,949 — 117,509 — $ 91,933 $ 33,780 $ 2,117,302 $ 118,160

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 16 – COMMITMENTS AND CONTINGENCIES Contractual Obligations and Commercial Commitments On February 20, 2017, we entered into a consulting agreement with a third party that has a twelve month term, and which can be extended by mutual agreement. The agreement provides for the issuance of a five (5) year warrant to the consultant, upon the execution of the agreement, to purchase 250,000 shares of our common stock at a price of $0.18 per share, plus the payment of $7,500 on the first day of each month, beginning March 1, 2016, coupled with the monthly issuance of five (5) year warrants to purchase our common stock in a number of shares determined by dividing $7,500 by $0.18 per share. These warrants are exercisable at a price of $0.18 per share. During the nine months ended September 30, 2017, we recognized $84,380 of expense applicable to this consulting agreement. On May 6, 2014, we entered into a consulting agreement with two third party consultants that has a nine month term, which can be renewed and/or extended by mutual agreement. Currently, the renewal of the agreement is under negotiation. The agreement provides for a $50,000 payment to the consultants at signing, which has been paid, and for three more $50,000 payments (a total of $200,000) and the issuance of 100,000 shares of our common stock upon the achievement of certain goals as set forth in appendix II of the agreement. During the three and nine months ended September 30, 2017 and 2016, we recognized no expenses applicable to this agreement At September 30, 2017 and December 31, 2016 the project was approximately 80% complete and $110,000 is included in accrued expenses on our consolidated balance sheets. The value of the 100,000 shares will be recognized upon achievement of the goals. The project has been suspended and it is unknown when it will resume. Financing Agreement – Equity Line of Credit On December 28, 2016, the Company entered into an equity line of credit agreement with Tangiers Global, LLC (“Tangiers”). Under the equity line agreement, Tangiers has agreed to provide the Company with up to $10,000,000 of funding through the purchase of shares of the Company’s common stock. During the term of the agreement, the Company may deliver a put notice to Tangiers, which will specify the number of shares which the Company will sell to Tangiers. The minimum amount the Company can draw down at any one time is $5,000, and the maximum amount the Company can draw down at any one time is $350,000 as determined by the formula contained in the equity line agreement. A closing will occur on the date which is no earlier than five trading days following, and no later than seven trading days following, the applicable put notice. On each closing date, the Company will sell, and Tangiers will purchase, the shares of the Company’s common stock specified in the put notice. The amount to be paid by Tangiers on a particular closing date will be determined by multiplying the purchase price by the number of shares specified in the put notice. The purchase price is 85% of the average of the two lowest trading prices of the Company’s common stock during the pricing period applicable to the put notice. The pricing period, with respect to a particular put notice, is five consecutive trading days including, and immediately following, the delivery of a put notice to Tangiers. The Company may submit a put notice once every ten trading days provided the closing of the previous transaction has taken place. The Company is under no obligation to submit any put notices. The Company has delivered seven (7) put notices to Tangiers as of September 30, 2017, and has received $1,380,204, under the terms of the equity line of credit agreement from the sale of 1,897,215 shares of our common stock to Tangiers. Subsequent to September 30, 2017, the Company delivered an additional put notice to Tangiers, and received $162,506, under the terms of the equity line of credit agreement from the sale of 267,703 shares of our common stock to Tangiers. Legal Proceedings We were not subject to any legal proceedings during the nine months ended September 30, 2017, and, to the best of our knowledge, no legal proceedings are pending or threatened.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2017
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 17 – SUBSEQUENT EVENTS Subsequent Analysis of Operations In accordance with ASC 855-10, we have analyzed our operations subsequent to September 30, 2017, to the date these condensed consolidated financial statements were issued, and have determined that, other than as disclosed above, we do not have any material subsequent events to disclose in these condensed financial statements. Research Agreement Under the terms of a research agreement entered into in October 2017 with the University of Florida Trustees (“UFT”), our subsidiary, Prana Therapeutics, Inc. committed to pay UFT $100,000, upon the execution of the research agreement, and $50,000 in each of the months of February 2018 and June 2018, for a total commitment of $200,000.

SUMMARY OF SIGNIFICANT ACCOUN24

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation
Principles of Consolidation	Principles of Consolidation
Use of Estimates	Use of Estimates We make our estimates of the ultimate outcome for these items based on historical trends and other information available when our condensed consolidated financial statements are prepared. We recognize changes in estimates in accordance with the accounting rules for the estimates, which are typically in the period when new information becomes available. We believe that our significant estimates, assumptions and judgments are reasonable, based upon information available at the time they were made. Our actual results could differ from these estimates, making it possible that a change in these estimates could occur in the near term.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Level 1 Level 2 Level 3 The carrying amount of our cash and cash equivalents, accounts receivable, accounts payable, and other current assets and liabilities in our consolidated financial statements approximates fair value because of the short-term nature of the instruments. Investments in non-marketable equity securities are carried at cost less other-than-temporary impairments. The carrying amount of our notes payable and convertible debt at September 30, 2017, approximates their fair values based on our incremental borrowing rates. There have been no changes in Level 1, Level 2, and Level 3 categorizations and no changes in valuation techniques for these assets or liabilities for the nine months ended September 30, 2017 and the year ended December 31, 2016.
Cash and Cash Equivalents	Cash and Cash Equivalents
Accounts Receivable	Accounts Receivable
Prepaid Expenses	Prepaid Expenses
Property and Equipment	Property and Equipment
Patents	Patents –
Intangible Assets	Intangible Assets –
Long-Lived Assets Impairment Assessment	Long-Lived Assets Impairment Assessment FASB Accounting Standards Codification
Equity Method Investments	Equity Method Investments
Goodwill	Goodwill
Purchase Price Allocation	Purchase Price Allocation Business Combinations Fair Value Measurements and Disclosures
Deferred Revenue	Deferred Revenue
Revenue Recognition	Revenue Recognition Revenue Recognition Revenue for services with a payment in the form of stock, warrants or other financial assets is recognized when the services are performed. The value of revenue paid with warrants is measured using the Black-Scholes-Merton pricing model. Revenue from product sales, including delivery fees, is recognized when an order has been obtained, the price is fixed and determinable, the product is shipped, title has transferred, and collectability is reasonably assured. Revenue Recognition – Affiliate Prana Prana Prana Prana Prana Prana Revenue Recognition.
Cost of Revenues	Cost of Revenues
Research and Development Expenses	Research and Development Expenses
General and Administrative Expenses	General and Administrative Expenses
Stock-Based Compensation	Stock-Based Compensation Equity We account for stock option grants issued and vesting to employees based on ASC 718, Compensation – Stock Compensation
Income Taxes	Income Taxes We follow the provisions of ASC 740, Income Taxes When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken, or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in our consolidated financial statements in the period during which, based on all available evidence, we believe it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured, as described above, is reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets, along with any associated interest and penalties that would be payable to the taxing authorities upon examination. Interest and penalties associated with unrecognized tax benefits, if any, are classified as interest expense and penalties and are included in selling, general and administrative expenses in our consolidated statements of operations.
Commitments and Contingencies	Commitments and Contingencies If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in our condensed consolidated financial statements. If the assessment indicates that a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the nature of the guarantee would be disclosed.
Net Loss Per Share	Net Loss Per Share Earnings per Share Potentially dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share, because the effect of their inclusion would have been anti-dilutive: Nine Months Ended Three Months Ended 2017 2016 2017 2016 Warrants to purchase common stock 641,000 666,667 641,000 666,667 Cashless warrants not converted to common stock 783,112 1,228,455 783,112 1,228,455 Stock options 6,580,000 3,680,000 6,580,000 3,680,000 8,004,112 5,575,122 8,004,112 5,575,122
Other Comprehensive Income (Loss)	Other Comprehensive Income (Loss)
Segment Reporting	Segment Reporting –
Concentration of Credit Risk	Concentration of Credit Risk The following tables show significant concentrations in our revenues and accounts receivable for the periods indicated: Percentage of Revenue: Nine Months Ended Three Months Ended September 30, September 30, 2017 2016 2017 2016 Customer A 82 % 88 % 98 % 80 % Customer B 17 % 12 % 2 % 20 % Customer C 1 % 0 % 0 % 0 % Percentage of Accounts Receivable: Nine Months Ended 2017 2016 Customer A 0 % 68 % Customer B 0 % 30 % Customer C 0 % 21 %
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In May 2014 the FASB issued guidance on revenue from contracts with customers, which implements a five-step process of how an entity should recognize revenue in order to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This guidance will be effective at the beginning of fiscal year 2018, and early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. We are currently evaluating the impact that the adoption will have on our condensed consolidated financial statements and related disclosures. We have not yet selected a transition method nor have we determined the effect of the standard on our ongoing reporting. In February 2016, the FASB issued guidance on leases which requires entities to recognize right-of-use assets and lease liabilities on the balance sheet for the rights and obligations created by all leases, including operating leases, with terms of more than 12 months. The new guidance also requires additional disclosures on the amount, timing, and uncertainty of cash flows arising from leases. These disclosures include qualitative and quantitative information. The new guidance will be effective for us at the beginning of fiscal year 2019. Early adoption is permitted. We are in the process of evaluating the impact the adoption of this guidance will have on our consolidated financial statements and related disclosures.

SUMMARY OF SIGNIFICANT ACCOUN25

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Schedule of potentially dilutive securities that have been excluded from the computation of diluted net loss per share, because the effect of their inclusion would have been anti-dilutive	Potentially dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share, because the effect of their inclusion would have been anti-dilutive: Nine Months Ended Three Months Ended 2017 2016 2017 2016 Warrants to purchase common stock 641,000 666,667 641,000 666,667 Cashless warrants not converted to common stock 783,112 1,228,455 783,112 1,228,455 Stock options 6,580,000 3,680,000 6,580,000 3,680,000 8,004,112 5,575,122 8,004,112 5,575,122
Schedule of significant concentrations in revenues and accounts receivable	The following tables show significant concentrations in our revenues and accounts receivable for the periods indicated: Percentage of Revenue: Nine Months Ended Three Months Ended September 30, September 30, 2017 2016 2017 2016 Customer A 82 % 88 % 98 % 80 % Customer B 17 % 12 % 2 % 20 % Customer C 1 % 0 % 0 % 0 % Percentage of Accounts Receivable: Nine Months Ended 2017 2016 Customer A 0 % 68 % Customer B 0 % 30 % Customer C 0 % 21 %

RECEIVABLE FROM AND EQUIPMENT26

RECEIVABLE FROM AND EQUIPMENT NOTE PAYABLE TO RELATED PARTY (Tables)	9 Months Ended
	Sep. 30, 2017
Related Party Transactions [Abstract]
Schedule of Amounts Due From Related Parties	Amounts due from related parties consist of: September 30, December 31, 2017 2016 Advesa, Inc. $ 35,083 $ 21,775 Employees 2,200 — Cannabinoid Research & Development, Limited — 5,000 $ 37,283 $ 26,775

PURCHASE OF PRANA THERAPUETIC27

PURCHASE OF PRANA THERAPUETICS, INC. (Tables)	9 Months Ended
	Sep. 30, 2017
Business Combinations [Abstract]
Schedule of allocation of purchase price	As of July 14, 2017, the allocation of the purchase price for the 95% fair value of Prana was comprised of: Patents $ 52,596 Net assets 450,888 Goodwill 4,567,016 Total $ 5,070,500

ACCRUED EXPENSES (Tables)

ACCRUED EXPENSES (Tables)	9 Months Ended
	Sep. 30, 2017
Accrued Liabilities, Current [Abstract]
Schedule of accrued expenses	Our accrued expenses consist of: September 30, 2017 December 31, 2016 Accrued consulting fees $ — $ 45,000 Accrued interest expense — 5,875 Accrued payroll taxes 38,244 — $ 38,244 $ 50,875

RESEARCH GRANT PAYABLE (Tables)

RESEARCH GRANT PAYABLE (Tables)	9 Months Ended
	Sep. 30, 2017
Other Liabilities Disclosure [Abstract]
Schedule of research grant payable	In August of 2013, we were received a grant from Accelerate Brain Cancer Cure, Inc. (“ABC”) in the amount of $75,000 to be used by us for the development and testing of brain cancer therapies (the “Grant”). Under the terms of the Grant, within 15 years after the effective date of the Grant, if one or more products resulting from the Grant is brought to market, then the Company will owe ABC the repayment of the Grant in the following amounts, based upon the following cumulative net profit benchmarks: Net Profit Grant $ 5,000,000 $ 75,000 15,000,000 75,000 30,000,000 75,000 50,000,000 75,000 $ 300,000

DEFERRED REVENUE (Tables)

DEFERRED REVENUE (Tables)	9 Months Ended
	Sep. 30, 2017
Deferred Revenue Disclosure [Abstract]
Schedule of deferred revenue	Our deferred revenue consists of: September 30, December 31, Deferred revenue - WeedMD $ 248,750 $ 383,750 Less - current portion (180,000 ) (180,000 ) Deferred revenue, net of current portion $ 68,750 $ 203,750

STOCKHOLDERS' EQUITY (DEFICIT)

STOCKHOLDERS' EQUITY (DEFICIT) (Tables)	9 Months Ended
	Sep. 30, 2017
Summary of stock options outstanding	The following table summarizes our stock options outstanding, as of September 30, 2017: Nine Months Ended September 30, 2017 Number of Shares Weighted Average Remaining Life (years) Weighted Average Exercise Price Stock options outstanding, beginning of period 3,680,000 8.9 $ $0.28 Issued 2,900,000 9.6 $0.56 Exercised — Expired — Stock options outstanding, end of period 6,580,000 8.8 $ $0.40 Stock options exercisable, September 30, 2017 6,580,000 8.8 $ $0.40
Summary of share warrants outstanding	The following table summarizes our share warrants outstanding as of September 30, 2017 and December 31, 2016: September 30, 2017 December 31, 2016 Number Weighted Number Weighted Warrants outstanding, beginning of period 1,449,779 $ 0.18 3,000,000 $ 12.00 Warrants issued to consultant 83,333 0.18 666,667 0.18 Warrants issued to consultant 16,000 1.25 — — Cashless issued upon conversion of Slainte note — 1,746,674 — Warrants exercised (125,000 ) 0.18 (963,562 ) — Expired — — (3,000,000 ) — Warrants outstanding, end of period 1,424,112 $ 0.19 1,449,779 $ 0.18 Warrants exercisable, end of period 1,424,112 $ 0.19 1,449,779 $ 0.18
Stock Options [Member]
Schedule of assumptions used for valuation utilizing the Black Scholes option pricing model for fair value	We calculated the fair value of each option to be approximately $0.70 per option utilizing the Black Scholes option pricing model and the following assumptions on the date of valuation: Stock price $ 0.70 Exercise price $ 0.70 Risk free interest rate 1.98 % Expected term (years) 10.0 Expected volatility 173 % Expected dividends 0 % We calculated the fair value of each option to be approximately $0.20 per option utilizing the Black Scholes option pricing model and the following assumptions on the date of valuation: Stock price $ 0.20 Exercise price $ .20 Risk free interest rate 1.98 % Expected term (years) 10.0 Expected volatility 173 % Expected dividends 0 %
Common Stock Issued for Warrant Outstanding [Member]
Schedule of assumptions used for valuation utilizing the Black Scholes option pricing model for fair value	We calculated the fair value of the Warrant to be $218,788, or approximately $1.29 per underlying share, utilizing the Black Scholes option pricing model and the following assumptions on the date of valuation: Stock price $ 1.59 Exercise price $ 3.00 Risk free interest rate 1.05 % Expected term (years) 2.6 Expected volatility 183 % Expected dividends 0 %

SHARE-BASED COMPENSATION (Table

SHARE-BASED COMPENSATION (Tables)	9 Months Ended
	Sep. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of share-based compensation expense	We recognize share-based compensation expense in cost of revenues and general and administrative expense based on the fair value of common shares issued for services. Share-based compensation expense for the three and nine months ended September 30, 2017 and 2016 is, as follows: Three Months Ended Nine Months Ended 2017 2016 2017 2016 Options granted to officers and directors for compensation $ — $ 33,780 $ 1,812,456 $ 118,160 Warrants and options issued for consulting services — — 16,379 — Common stock issued for services 68,984 — 170,958 — Common stock accrued as payment for services, shares not yet issued 22,949 — 117,509 — $ 91,933 $ 33,780 $ 2,117,302 $ 118,160

BUSINESS ORGANIZATION AND NAT33

BUSINESS ORGANIZATION AND NATURE OF OPERATIONS (Details) - USD ($)	Jul. 14, 2017	Mar. 31, 2014	Sep. 30, 2017	May 31, 2017	Dec. 31, 2016	Mar. 26, 2014
Amount of payable owed to former officer and director, exchanged for assets sold		$ 15,000
Number of common shares issued in exchange for certain intellectual property		38,690,000
Total number of common shares previously outstanding, cancelled during period						41,690,000
Common stock, shares outstanding			60,210,502		50,650,994	43,620,000
Closing price per share				$ 0.56
Prana [Member]
Common shares received in exchange for future consulting services and use of our intellectual property	5,730,000
Fair market value of common stock	$ 5,070,500
Closing price per share	$ 0.85
Prana [Member] | Subscription Agreement [Member]
Shares of investment owned	400,000
Investments in non-marketable equity securities	$ 200,000		$ 50,000

SUMMARY OF SIGNIFICANT ACCOUN34

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)	9 Months Ended
	Sep. 30, 2017USD ($)Item	Sep. 30, 2016USD ($)	Dec. 31, 2016USD ($)
Number of operating segment | Item	1
Allowance for doubtful accounts	$ 0		$ 4,340
Bad debt expense		$ 25,660
Excess of purchase price over fair values of net tangible assets and intangible assets recorded as goodwill	4,733,410
Goodwill	$ 4,912,201
PTI [Member]
Equity Method Investments, Percentage	95.00%
Purchase Price Allocation	$ 5,070,500
Goodwill	4,567,016
Prana [Member]
Goodwill	$ 4,805,328
CRD [Member]
Equity Method Investments, Percentage	50.00%
Goodwill	$ 106,873
Chief Executive Officer [Member]
Cash equivalents	$ 4,158		$ 4,158
Minimum [Member]
Estimated useful lives of property and equipment	3 years
Estimated useful lives of intangible assets	10 years
Maximum [Member]
Estimated useful lives of property and equipment	5 years
Estimated useful lives of intangible assets	15 years
Patents [Member]
Estimated useful lives of intangible assets	15 years

SUMMARY OF SIGNIFICANT ACCOUN35

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of anti-dilutive securities) (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted net loss per share	8,004,112	5,575,122	8,004,112	5,575,122
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted net loss per share	6,580,000	3,680,000	6,580,000	3,680,000
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted net loss per share	641,000	666,667	641,000	666,667
Cashless warrants not converted to common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted net loss per share	783,112	1,228,455	783,112	1,228,455

SUMMARY OF SIGNIFICANT ACCOUN36

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of concentration of credit risk) (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenue [Member] | Customer A [Member]
Concentration Risk [Line Items]
Concentration risk percentage	98.00%	80.00%	82.00%	88.00%
Revenue [Member] | Customer B [Member]
Concentration Risk [Line Items]
Concentration risk percentage	2.00%	20.00%	17.00%	12.00%
Revenue [Member] | Customer C [Member]
Concentration Risk [Line Items]
Concentration risk percentage	0.00%	0.00%	1.00%	0.00%
Accounts Receivable [Member] | Customer B [Member]
Concentration Risk [Line Items]
Concentration risk percentage			0.00%	30.00%
Accounts Receivable [Member] | Customer C [Member]
Concentration Risk [Line Items]
Concentration risk percentage			0.00%	21.00%
Accounts Receivable [Member] | Customer A [Member]
Concentration Risk [Line Items]
Concentration risk percentage			0.00%	68.00%

GOING CONCERN (Details)

GOING CONCERN (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
GOING CONCERN [Abstract]
Net loss	$ 653,706	$ 296,575	$ 3,729,687	$ 962,953
Net cash used in operating activities			1,037,264	$ 258,607
Working capital deficit	145,886		145,886
Accumulated deficit	12,849,876		12,849,876		$ 9,362,333
Line of credit agreement	$ 1,380,204		1,380,204
Payment to purchase common stock			$ 10,000,000

RECEIVABLE FROM AND EQUIPMENT38

RECEIVABLE FROM AND EQUIPMENT NOTE PAYABLE TO RELATED PARTY (Narrative) (Details) - USD ($)	9 Months Ended
	Sep. 30, 2017	Dec. 31, 2016	Apr. 20, 2015
Related Party Transaction [Line Items]
Due from related parties	$ 37,283	$ 26,775
CRD [Member]
Related Party Transaction [Line Items]
Due from related parties			$ 5,000
Advesa [Member]
Related Party Transaction [Line Items]
Interest rate	7.50%
Lease term of laboratory equipment	36 months
Due from related parties	$ 35,083	$ 21,775

RECEIVABLE FROM AND EQUIPMENT39

RECEIVABLE FROM AND EQUIPMENT NOTE PAYABLE TO RELATED PARTY (Schedule of Amount Due from Related Parties) (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Related Party Transaction [Line Items]
Due from related parties	$ 37,283	$ 26,775
CRD [Member]
Related Party Transaction [Line Items]
Due from related parties		5,000
Advesa [Member]
Related Party Transaction [Line Items]
Due from related parties	35,083	21,775
Employees [Member]
Related Party Transaction [Line Items]
Due from related parties	$ 2,200

PURCHASE OF PRANA THERAPUETIC40

PURCHASE OF PRANA THERAPUETICS, INC. (Narrative) (Details) - USD ($)	Jul. 14, 2017	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	May 31, 2017
Business Acquisition [Line Items]
Closing price per share					$ 0.56
Prana [Member]
Business Acquisition [Line Items]
Common shares received in exchange for future consulting services and use of our intellectual property	5,730,000
Fair market value of common stock	$ 5,070,500
Closing price per share	$ 0.85
Shares issued in acquisition	400,000
Shares issued in acquisition, value	$ 200,000
Prana [Member] | Subscription Agreement [Member]
Business Acquisition [Line Items]
Shares of investment owned	400,000
Investments in non-marketable equity securities	$ 200,000			$ 50,000
Prana [Member] | Subscription Agreement [Member] | Subsequent Event [Member]
Business Acquisition [Line Items]
Investments in non-marketable equity securities		$ 50,000	$ 50,000

PURCHASE OF PRANA THERAPUETIC41

PURCHASE OF PRANA THERAPUETICS, INC. (Schedule of Purchase Price Allocation) (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Business Acquisition [Line Items]
Goodwill	$ 4,912,201
PTI [Member]
Business Acquisition [Line Items]
Patents	52,596
Net assets	450,888
Goodwill	4,567,016
Purchase Price Allocation	$ 5,070,500

PATENTS (Details)

PATENTS (Details) - Patents [Member] - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Jul. 15, 2017
Finite-Lived Intangible Assets [Line Items]
Estimated useful live	15 years
Amortization expense	$ 900	$ 0
Accumulated amortization	$ 900	$ 0
Research, legal fees			$ 142,317

INTANGIBLES (Details)

INTANGIBLES (Details)	9 Months Ended
	Sep. 30, 2017
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life	15 years
Design Marks and Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life	10 years

EQUITY METHOD INVESTMENTS (Narr

EQUITY METHOD INVESTMENTS (Narrative) (Details) - USD ($)	Aug. 15, 2014	Sep. 30, 2017	Dec. 31, 2016
Schedule of Equity Method Investments [Line Items]
Equity method investments			$ 88,000
CRD [Member]
Schedule of Equity Method Investments [Line Items]
Interest acquired	50.00%
Equity method investments	$ 88,000
Shares of common stock issuable for acquisition of interest	40,000

ACCRUED EXPENSES (Narrative) (D

ACCRUED EXPENSES (Narrative) (Details) - USD ($)	May 06, 2014	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2014	Dec. 31, 2015
Accrued expenses		$ 38,244		$ 38,244		$ 50,875
Loss on extinguishment of debt				$ 267,567	$ 130,423
Research and Development Arrangement [Member]
Consultancy agreement, term	9 months
Consultancy agreement, initial payment	$ 50,000
Consultancy agreement, additional payments	50,000
Consultancy agreement, total payments	$ 200,000
Shares issued for consultancy agreement	100,000					100,000
Costs recognized							$ 160,000
Accrued expenses								$ 110,000
Percentage of completion								80.00%
Fair value of shares						$ 163,783
Loss on extinguishment of debt						$ 53,783

ACCRUED EXPENSES (Details)

ACCRUED EXPENSES (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Accrued Liabilities, Current [Abstract]
Accrued consulting fees		$ 45,000
Accrued interest expense		5,875
Accrued payroll taxes	38,244
Total accrued expenses	$ 38,244	$ 50,875

RESEARCH GRANT PAYABLE (Schedul

RESEARCH GRANT PAYABLE (Schedule of Research Grant Payable) (Details)	Sep. 30, 2017USD ($)
Other Commitments [Line Items]
Grant Repayment Amount	$ 75,000
Grant [Member]
Other Commitments [Line Items]
Net Profit Benchmarks	5,000,000
Grant Repayment Amount	75,000
Grant One [Member]
Other Commitments [Line Items]
Net Profit Benchmarks	15,000,000
Grant Repayment Amount	75,000
Grant Two [Member]
Other Commitments [Line Items]
Net Profit Benchmarks	30,000,000
Grant Repayment Amount	75,000
Grant Three [Member]
Other Commitments [Line Items]
Net Profit Benchmarks	50,000,000
Grant Repayment Amount	$ 75,000

DEFERRED REVENUE (Narrative) (D

DEFERRED REVENUE (Narrative) (Details) - USD ($)	Jun. 09, 2014	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2014	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 28, 2014
Fox Barry Farms Llc [Member]
Deferred Revenue Arrangement [Line Items]
Prepaid royalty payment								$ 200,000
Deferred income recognized other income							$ 200,000
WeedMD RX Inc. (''WMD'') [Member]
Deferred Revenue Arrangement [Line Items]
Common shares received in exchange for future consulting services and use of our intellectual property	1,187,500
Warrants received in exchange for future consulting services and use of our intellectual property	3,000,000
Fair value of securities recorded as deferred revenue	$ 893,750
Deferred revenue recognized per month		$ 15,000	$ 15,000		$ 15,000	$ 15,000
Total deferred revenue recognized		45,000	$ 90,000	$ 150,000	45,000	$ 90,000	180,000
Deferred revenue		$ 248,750			$ 248,750		$ 383,750

DEFERRED REVENUE (Schedule of d

DEFERRED REVENUE (Schedule of deferred revenue) (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Deferred Revenue Arrangement [Line Items]
Less - current portion	$ (180,000)	$ (180,000)
Deferred revenue, net of current portion	68,750	203,750
WeedMD RX Inc. (''WMD'') [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenue	$ 248,750	$ 383,750

STOCKHOLDERS' DEFICIT (Stock Op

STOCKHOLDERS' DEFICIT (Stock Option Activity) (Narrative) (Details) - USD ($)	Jul. 18, 2017	Feb. 10, 2016	Sep. 30, 2017	Dec. 31, 2016	May 31, 2017	Jan. 12, 2016	Jan. 12, 2015	Jan. 09, 2015
Preferred stock, shares authorized			10,000,000	10,000,000
Preferred stock, no par value
Common stock, shares authorized			100,000,000	100,000,000
Common stock, no par value
Awarded stock options				$ 3,080,000
Share price of common stock					$ 0.56
Fair value of warrants				$ 612,512
Series A Preferred Stock [Member] | Officer and Director [Member]
Share issued	2,000
Proceeds from shares issued	$ 2,200
Stock Options [Member]
Awarded stock options			$ 57,500
Share price of common stock			$ 0.92
Maturity date			Jul. 26, 2018
Mr. Ruby [Member]
Awarded stock options					$ 2,600,000
Blackmon [Member]
Awarded stock options					100,000
Tony Verzura [Member]
Awarded stock options					100,000
Non Officer Consultant [Member]
Awarded stock options					$ 100,000
2014 Stock Incentive Plan [Member] | Mr. Ruby [Member]
Common stock, par value per share							$ 0.20
Awarded stock options							$ 980,000
Stock Options [Member]
Awarded stock options						$ 1,050,000		$ 200,000
Stock options			6,580,000	3,680,000				600,000
Weighted-average remaining contractual life for stock options outstanding and exercisable			8 years 9 months 18 days
Share price of common stock						$ 0.20		$ 0.70
Stock Options [Member]
Stock options				600,000
Fair value of options				417,664
Common Stock Issued for Warrant Outstanding [Member]
Awarded stock options		$ 987,390
Stock options		621,000
Share price of common stock		$ 1.59
Fair value of warrants		$ 218,788
Warrant issued to purchase common stock		170,044
Fair value of common shares issued in excess		$ 768,602

STOCKHOLDERS' DEFICIT (Schedule

STOCKHOLDERS' DEFICIT (Schedule of Assumptions on Date of Valuation Utilizing for Fair Value of Warrants) (Details) - $ / shares	Feb. 10, 2016	Jan. 12, 2016	Jan. 09, 2015	May 31, 2017
Stock price (in dollars per share)				$ 0.56
Stock Options [Member]
Stock price (in dollars per share)		$ 0.20	$ 0.70
Exercise price (in dollars per share)		$ 0.20	$ 0.70
Risk free interest rate (as a percent)		1.98%	1.98%
Expected term (years)		10 years	10 years
Expected volatility (as a percent)		173.00%	173.00%
Expected dividends (as a percent)		0.00%	0.00%
Common Stock Issued for Warrant Outstanding [Member]
Stock price (in dollars per share)	$ 1.59
Exercise price (in dollars per share)	$ 3
Risk free interest rate (as a percent)	1.05%
Expected term (years)	2 years 7 months 6 days
Expected volatility (as a percent)	183.00%
Expected dividends (as a percent)	0.00%

STOCKHOLDERS' DEFICIT (Schedu52

STOCKHOLDERS' DEFICIT (Schedule of stock option activity) (Details) - $ / shares	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Number of Shares
Issued		33,780	1,812,456	118,160
Stock Options [Member]
Number of Shares
Stock options outstanding, beginning of period			3,680,000
Issued			2,900,000
Exercised
Expired
Stock options outstanding, end of period	6,580,000		6,580,000		3,680,000
Stock options exercisable, September 30, 2017	6,580,000		6,580,000
Weighted Average Exercise Price
Stock options outstanding, beginning of period			$ 0.28
Issued			0.56
Exercised
Expired
Stock options outstanding, end of period	$ 0.40		0.40		$ 0.28
Stock options exercisable, September 30, 2017	$ 0.40		$ 0.40
Weighted Average Remaining Life (Years)
Stock options outstanding			8 years 9 months 18 days		8 years 10 months 25 days
Stock options Issued			9 years 7 months 6 days
Stock options exercisable			8 years 9 months 18 days

STOCKHOLDERS' DEFICIT (Common S

STOCKHOLDERS' DEFICIT (Common Stock Issued For Services, Warrants) (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Number of Shares
Warrants outstanding, beginning of period	1,449,779	3,000,000
Warrants issued to consultant	83,333	666,667
Warrants issued to consultant	16,000
Cashless issued upon conversion of Slainte note		1,746,674
Warrants exercised	(125,000)	(963,562)
Expired		(3,000,000)
Warrants outstanding, end of period	1,424,112	1,449,779
Warrants exercisable at the end of the period (in shares)	1,424,112	1,449,779
Weighted Average Exercise Price
Warrants outstanding, beginning of period (in dollars per share)	$ 0.18	$ 12
Warrants issued to consultant	0.18	0.18
Warrants issued to consultant	$ 1.25
Cashless issued upon conversion of Slainte note
Warrants exercised	$ 0.18
Expired
Warrants outstanding, end of period	0.19	0.18
Warrants exercisable at the end of the period (in shares)	$ 0.19	$ 0.18

SHARE-BASED COMPENSATION (Detai

SHARE-BASED COMPENSATION (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Options granted to officers and directors for compensation		33,780	1,812,456	118,160
Warrants and options issued for consulting services			$ 16,379
Common stock issued for services	68,984		170,958
Common stock accrued as payment for services, shares not yet issued	22,949		117,509
Share-based compensation	$ 91,933	$ 33,780	$ 2,117,302	$ 118,160

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details) - USD ($)	Dec. 28, 2016	May 06, 2014	Feb. 20, 2017	Sep. 30, 2017	Dec. 31, 2016
Fair value of warrants					$ 612,512
Accrued expenses				$ 38,244	50,875
Payment to purchase common stock				10,000,000
Line of credit				1,380,204
Contractual Obligations and Commercial Commitments [Member]
Consulting agreement term			12 months
Warrant issued to purchase common stock		100,000
Consulting agreement expense				84,380
Consultants signing amount		$ 50,000
Consultants amount, net		$ 200,000
Accrued expenses				$ 110,000	$ 110,000
Project completion percentage				80.00%	80.00%
Contractual Obligations and Commercial Commitments [Member] | Warrant [Member]
Consulting agreement term			5 years
Warrant issued to purchase common stock			250,000
Warrant exercise price			$ 0.18
Payment to agreement monthly basis			$ 7,500
Tangiers [Member]
Payment to purchase common stock	$ 10,000,000
Tangiers [Member] | 7 put notices [Member]
Line of credit				$ 1,380,204
Number of shares sold				1,897,215
Tangiers [Member] | Put notices [Member]
Line of credit				$ 162,506
Number of shares sold				267,703
Tangiers [Member] | Minimum [Member]
Line of credit	5,000
Tangiers [Member] | Maximum [Member]
Line of credit	$ 350,000

SUBSEQUENT EVENTS (Narrative) (

SUBSEQUENT EVENTS (Narrative) (Details) - Prana [Member] - Subsequent Event [Member]	Oct. 31, 2017USD ($)
Subsequent Event [Line Items]
Total commitment upon execution of research agreement	$ 100,000
Commitment owed in February 2018	50,000
Commitment owed in June 2018	50,000
Total commitment amount owed	$ 200,000